Overall Learning Objectives:

1. Recognize and diagnose fatty liver disease, including MASLD and MASH, in at-risk patient populations through appropriate screening and assessment tools.

2. Select and interpret appropriate diagnostic investigations to evaluate suspected cases of fatty liver disease.

3. Implement evidence-based treatment strategies for patients with hepatic steatosis, tailoring interventions to individual risk profiles and disease severity.

4. Identify and refer patients with advanced or high-risk fatty liver disease to specialized care for further management.

 

MODERATOR: JEFFREY LAZARUS

Thursday, December 4, 2025
6:00 PM - 6:05 PM
Welcome & Opening Remarks
 
Michael Betel, Fatty Liver Alliance
Marko Korenjak, European Liver Patients’ Association
Juan Manuel Mendive, European Society For Primary Care Gastroenterology (ESPCG)
6:05 PM - 6:30 PM
Understanding MASLD and MASH and the relationship between Primary Care and the Hepatologist
  • Define MASLD and MASH using current, practical terminology.
  • Identify key screening criteria and risk factors for fatty liver disease in primary care.
  • Summarize updated guidelines and nomenclature relevant to MASLD and MASH.
Jörn Schattenberg, University Medical Center Homburg
6:30 PM - 7:00 PM
Primary Care Toolbox: Managing Fatty Liver in Daily Practice
  • Select appropriate laboratory and non-invasive tests for the assessment of fatty liver disease.
  • What labs to order
  • Demonstrate how to integrate liver health assessments into routine patient visits.
  • Interpret results from NITs (FIB-4, Transient Elastography, ultrasound, ELF, and non-invasive scores) and determine when to use each tool.
  • Apply workflow strategies to optimize efficiency and improve patient care in primary care settings.
Louise Campbell, Tawazun Health
Jeffrey V. Lazarus, Barcelona Institute for Global Health (ISGLOBAL)
7:00 PM - 7:25 PM
The Patient Voice: MASLD/MASH Real-World Experience
  • Describe common barriers patients face in accessing care for MASLD/MASH (e.g., stigma, confusion, fear).
  • Discuss patient experiences and factors that contributed to successful management.
  • Assess the impact of primary care interventions on patient outcomes.
José Willemse, Liver Patients International
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow
7:25 PM - 7:55 PM
Lifestyle Rx: Pearls for a busy Primary Care Practice
  • Addressing real world nutritional advice – Practical strategies for Primary Care
  • Addressing real world exercise advice - Practical strategies for Primary Care
  • Recommend practical nutritional and lifestyle strategies for patients with fatty liver disease.
  • Address patient challenges and stigma related to lifestyle modification.
  • Demonstrate brief, effective lifestyle interventions suitable for busy clinical settings
Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Jonathan Stine, Penn State Health Milton S. Hershey Medical Center
7:55 PM - 8:25 PM
Integrating Available Treatment Approaches in Primary Care for management of Fatty Liver disease
  • Review the role of GLP-1s, statins, insulin sensitizers, and emerging therapies in MASLD/MASH management.
  • Evaluate medication choices considering comorbidities such as T2D, obesity, CKLM and bariatric surgery
  • Summarize current and upcoming guidelines for pharmacologic management.
Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN
8:25 PM - 8:55 PM
Case-Based Panel: What Would You Do?
  • Analyze real-world cases to identify appropriate diagnostic and management strategies for diabetes and obesity
  • Evaluate patient with advanced fibrosis on Transient Elastography but no symptoms
  • Evaluate Young patient with obesity and normal liver enzymes
  • Differentiate between patients who require specialist referral and those manageable in primary care.
  • Formulate individualized care plans based on case scenarios.
James KIM, University of Calgary
Aleksander Krag, Odense University Hospital
Vlad Ratziu, Hospital Pitié salpêtrière, ICAN
Shira Zelber-Sagi Shira, University of Haifa, EASL, researcher at GNC
Una Keightley, Dr. Stephen A. Harrison Advocacy Fellow
8:55 PM - 9:00 PM
Closing Remarks: Primary Care as Liver Health Leaders
 
Michael Betel, Fatty Liver Alliance
Time Zone: (UTC+01:00) Berlin, Bern [Change Time Zone]

*Content subject to changes